Vnitr Lek 2021, 67(3):150-155 | DOI: 10.36290/vnl.2021.036

Treatment strategies for myelodysplastic syndrome in 2021

Petra Bělohlávková
IV. interní hematologická klinika, LF UK a FN Hradec Králové

The heterogeneous nature of myelodysplastic syndrome (MDS) brings a very variable prognosis of patients with the need for individualized treatment. The prognosis and treatment depend on the conventional determination of IPSS (International Prognostic Scoring System) and its revised form IPSS-R, which divides patients into lower and higher risk groups. Treatment of patients with lower risk of MDS include the improvement of cytopenia, especially anemia. The goal of treatment in patients with higher risk of MDS is delaying disease progression and improve patient survival. The only curative method for therapy of MDS is allogeneic hematopoietic stem cell transplantation (HSCT), howewer it is rarely applicable due to the age and comorbidities of patients.

Keywords: azacitidin, erythropoiesis-stimulating agents, myelodysplastic syndromes, lenalidomide, treatment.

Published: May 26, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bělohlávková P. Treatment strategies for myelodysplastic syndrome in 2021. Vnitr Lek. 2021;67(3):150-155. doi: 10.36290/vnl.2021.036.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Malcovati L, Hellström-Lindberg E, Bowen D et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet, Blood. 2013; 122: 2943-2964. Go to original source... Go to PubMed...
    2. Arber DA, Orazi A, Hasserjian R et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127: 2391-2405. Go to original source... Go to PubMed...
    3. Greenberg PL, Tuechler H, Schanz J et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120: 2454-2465. Go to original source... Go to PubMed...
    4. Platzbecker U. Treatment of MDS. Blood. 2019; 7: 133(10): 1096-1107. Go to original source... Go to PubMed...
    5. Fenaux P, Platzbecker U, Ades L. How we manage adults with myelodysplastic syndrome. Br J Haematol. 2019. doi: 10.1111/bjh.16206. Go to original source... Go to PubMed...
    6. Gascón P, Krendyukov A, Mathieson N, Aapro M. Epoetin Alfa for the Treatment of Myelodysplastic Syndrome-Related Anemia: A Review of Clinical Data, Clinical Guidelines, and Treatment Protocols. Leuk Res. 2019; 81: 35-42. Go to original source... Go to PubMed...
    7. Komrokji RS, List AF. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes. Ann Oncol. 2016; 27: 62-68. Go to original source... Go to PubMed...
    8. Jonášová A, Červinek L, Bělohlávková P et al. První české zkušenosti s lenalidomidem v terapii anemických nemocných s myelodysplastickým syndromem s delecí dlouhého ramene 5. chromozomu, Vnitr Lek. 2015; 61(12): 1028-1033. Go to PubMed...
    9. Santini V, Almeida A, Giagounidis A et al. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. J. Clin. Oncol. 2016; 34: 2988-2996. Go to original source... Go to PubMed...
    10. Kantarjian HM, Fenaux P, Sekeres MA et al. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Lancet Haematol. 2018; 5: e117-26.10. Go to original source... Go to PubMed...
    11. Langemeijer S, De Swart L, Yu G, Smith A, Crouch S, Johnston T et al. Impact of treatment with iron chelators in lower-risk MDS patients participating in the European leukemianet MDS (EUMDS) registry. Blood. 2016; 128(22): 3186. Go to original source...
    12. Gattermann N. Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation? Hematol Oncol Clin North Am. 2020; 34(2): 465-473. Go to original source... Go to PubMed...
    13. Stahl M, Bewersdorf JP, Giri S et al. Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis Haematologica 2020; 105(1): 102-111. Go to original source... Go to PubMed...
    14. de Witte T, Bowen D, Robin M et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. 2017; 129(13): 1753-1762.
    15. Zeidan AM, Stahl M, DeVeaux M, Giri S, Huntington S, Podoltsev N et al. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates? Blood Cancer J; 2018; 8: 55. Go to original source... Go to PubMed...
    16. Fenaux P. The Medalist Trial: results of a phase 3, randomized, double-blind, placebo- controlled study of luspatercept to treat anemia in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) who require red blood cell (RBC) transfusions. Blood. 2018; 132(Suppl 1): 1. Go to original source... Go to PubMed...
    17. Platzbecker U, Germing U, Götze KS et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017; 18: 1338-1347. Go to original source... Go to PubMed...
    18. Steensma DP, Platzbecker U, Van Eygen K et al. Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive. Blood. 2018; 132: 463. Go to original source...
    19. Fenaux P, Raza A, Vellenga E, Platzbecker U, Santini V, Samarina I. Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge). Blood. 2017; 130: 4256.
    20. Yang Y, Yu X, Zhang Y et al. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury. Clin. Sci. 2018; 132: 825-838. Go to original source... Go to PubMed...
    21. Henry JG, Glaspy J, Harrup RA et al. Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB). Blood. 2019; 134. (Supplement 1) Go to original source...
    22. Sekeres MA, Othus M, List AF et al. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG s1117. J Clin Oncol. 2017; 35(24): 2745-2753. Go to original source... Go to PubMed...
    23. Dickinson M, Honar Cherif H, Fenaux P et al. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018; 132: 2629-2638. Go to original source... Go to PubMed...
    24. Sekeres MA, Watts J, Radinof A et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia. 2021 Jan 22. doi: 10.1038/s41375-021-01125-4. Online ahead of print. Go to original source... Go to PubMed...
    25. Wei AH, Strickland SA Jr, Hou JZ et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol 2019; 37: 1277-1284. Go to original source... Go to PubMed...
    26. Garcia-Manero G, Roboz G, Walsh K et al. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Hematol. 2019; 6: 317-327. Go to original source... Go to PubMed...
    27. Navada SC, Garcia-Manero G, Atallah EL et al. Phase II study of oral rigosertib combined with azacitidine (AZA) as first line therapy in patients (Pts) with higher-risk myelodysplastic syndromes (HR-MDSt]. American Society of Hematology. 2019. http:// dx.doi.org/10.1182/blood-2019-131676. Go to original source...
    28. DiNardo CD, Watts JM, Stein EM, de Botton S, Fathi AT, Prince GT et al. Ivosidenib (AG-120) induced durable remissions and transfusion independence in patients with IDH1-mutant relapsed or refractory myelodysplastic syndrome: results from a phase 1 dose escalation and expansion study. Blood. 2018; 132: 1812. Go to original source...
    29. Sallman DA, DeZern AE, Garcia-Manero G et al. Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML). Blood. 2019; 134(Supplement 1): 676-676. Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.